- In early March 2026, Veeva Systems reported fourth-quarter revenue of US$835.95 million and net income of US$244.2 million, alongside higher full-year revenue of US$3.20 billion and net income of US$908.91 million, and issued guidance calling for continued revenue growth in fiscal 2027.
- The company also highlighted expanding adoption of its Vault CRM platform and new wins such as AOP Health’s broad use of Veeva’s Development, Quality, Commercial, and Data Clouds, underlining its role as a core software provider to life sciences customers.
- Next, we’ll examine how Veeva’s stronger guidance and growing Vault CRM adoption interact with the existing investment narrative and expectations.
Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
Veeva Systems Investment Narrative Recap
To own Veeva Systems, you need to believe its specialized cloud software will remain central to how life sciences companies run clinical, quality, and commercial workflows. The key short term catalyst is execution against fiscal 2027 revenue guidance of US$3.59–US$3.60 billion, while the biggest risk is intensifying competition from broader cloud vendors. The latest earnings and guidance support the existing thesis rather than materially changing that risk reward balance.
The most relevant update here is Veeva’s disclosure that more than 125 customers, including multiple top 20 biopharmas, are already live on Vault CRM. This traction, combined with an accelerated end of support date for legacy Veeva CRM in December 2029, ties directly into the migration catalyst and highlights how quickly large customers are standardizing on the new platform, even as adoption risk and potential customer fatigue remain real considerations.
Yet even with solid guidance and growing Vault CRM adoption, investors should be aware of how rising competition could pressure pricing and renewal terms...
Read the full narrative on Veeva Systems (it's free!)
Veeva Systems' narrative projects $4.3 billion revenue and $1.3 billion earnings by 2028. This requires 12.8% yearly revenue growth and about a $490 million earnings increase from $809.9 million today.
Uncover how Veeva Systems' forecasts yield a $270.93 fair value, a 46% upside to its current price.
Exploring Other Perspectives
Some of the most pessimistic analysts were assuming Veeva’s revenue would only reach about US$4.3 billion by 2029 with flat margins, so if Development Cloud adoption or AI agents ramp faster than they expect, the gap between today’s cautious narrative and a stronger long term outcome could be wider than it looks on paper.
Explore 6 other fair value estimates on Veeva Systems - why the stock might be worth as much as 46% more than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Veeva Systems research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free Veeva Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Veeva Systems' overall financial health at a glance.
Ready For A Different Approach?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com